Tech Trends That WON'T Happen in 2025: AI-RAN, Consumer Smart Glasses, Humanoids, and Semiconductor Onshoring - To Name a Few

ABI Research's 5^th annual Trend Report identifies the 53 key technology trends that will come to fruition—and the 48 that won't—in 2025

NEW YORK, Dec. 12, 2024 /PRNewswire/ -- As 2025 kicks off, predictions abound on the technology innovations expected in the year ahead. However, several highly anticipated advancements, including AI-RAN, Consumer Smart Glasses, Humanoids, and Semiconductor Onshoring, will NOT happen in 2025, states global technology intelligence firm ABI Research.

In its new whitepaper, 101 Technology Trends That Will—and Won't—Shape 2025, ABI Research analysts identify 54 trends that will shape the technology market and 47 others that, although attracting vast amounts of speculation and commentary, are less likely to move the needle over the next twelve months.

"2024 has been marked by challenges, from global conflicts and inflationary pressures to political uncertainty. These factors have strained enterprise and consumer spending, leading to market inertia, short-term technology investments, sidelined capital, and the exposure of vulnerable suppliers," says Stuart Carlaw, Chief Research Officer at ABI Research. "From a technology perspective, many industries and end markets are in that awkward stage of technology adoption where they are formulating implementation strategies, assessing solutions and partners, and trying to see if they have the resources needed to roll out solutions at scale. This is a particularly sensitive time, which tends to suggest 2025 will have tech implementers and end users on the brink of a period of a massive technology shift as they work through these issues."

What Won't Happen in 2025:

AI-RAN Will Not Be Widely Deployed
Despite rapid progress, Artificial Intelligence (AI) technology for the RAN ecosystem (AI-RAN) remains in early development, with commercial deployments not expected before 2026. SoftBank recently completed a trial and plans deployment by 2026, with broader adoption likely by 2027, given Japan's history as an early tech adopter. In 2025, trials and pilot projects will advance the technology, but large-scale deployment will take longer to materialize.

Consumer Smart Glasses Will Not See Adoption at Scale
Despite the significant strides that we will see in AI, smart glasses are expected to remain predominantly in the realm of early adopters. In terms of consumer adoptions, Virtual Reality (VR) will maintain its strongest foothold in gaming, sports, and fitness, where immersive experiences have already proven their value and consumer demand remains. While some companies will hit the market with early products and developer solutions, such as Snapchat with its newest Spectacles, 2025 will still be another transitional year for smart glasses, with most traction coming from niche applications, rather than widespread consumer or at-scale deployment.

Humanoids Will Not Take Over the World
Funding will continue to be drawn to humanoid development due to the societal issues the technology promises to address. The year 2025 is also when China intends to become the global humanoid leader. However, humanoids are not yet ready to experience widescale uptake. Significant advances have been made in hardware—now there are a dozen humanoids as advanced as Boston Dynamics' Atlas—while teleoperation has demonstrated impressive performance. Humanoids will struggle to advance much beyond this point without a radical step change in AI. Despite this technical shortfall, automotive manufacturing will continue to be the proving ground for humanoid robots and more manufacturers will buy into the form factor in 2025.

Semiconductor Onshoring Dreams Will Not Come True
The year 2025 will be a pivotal reality check for U.S. and European semiconductor onshoring efforts, as implementation challenges force significant delays. Despite the U.S. CHIPS Act's US$7.86 billion grant to Intel and ambitious US$100 billion investment plans, key projects like Intel's Arizona and Ohio sites, TSMC's Arizona fab, and Europe's Magdeburg facility face setbacks due to EUV machine shortages, workforce gaps, and operational complexities. Full operational capacity is unlikely before 2027, jeopardizing the EU's goal of 20% global chip production by 2030. These obstacles will prompt a strategic reassessment in 2025, shifting focus from full onshoring to pragmatic diversification and trusted partnerships. The semiconductor cold war may also slow innovation in AI and other advanced technologies reliant on cutting-edge chips.

"This coming year will be key in understanding how Artificial Intelligence, Generative Artificial Intelligence (Gen AI), the cloud, the edge, the hybrid cloud, Extended Reality (XR), enterprise 5G, and the ambient Internet of Things (IoT) will develop. Much is needed in terms of shifting from visioneering to real-world marketing, education, marketing around alleviating pressing endemic risks, and shifting to smaller practical revenue-generating implementations, rather than trying to "boil the ocean." We look forward to helping our clients navigate the intricacies of 2025. Focusing on customer value, driving ROI, and addressing endemic issues will be key factors to success," Carlaw concludes.

For more trends that won't happen in 2025 and the 53 trends that will, download the whitepaper, 101 Technology Trends That Will—and Won't—Shape 2025.

About ABI Research

ABI Research is a global technology intelligence firm uniquely positioned at the intersection of technology solution providers and end-market companies. We serve as the bridge that seamlessly connects these two segments by providing exclusive research and expert guidance to drive successful technology implementations and deliver strategies proven to attract and retain customers.

ABI Research是一家全çƒæ€§çš„技术情报公å¸ï¼Œæ‹¥æœ‰å¾—天独厚的优势，充当终端市场公å¸å’ŒæŠ€æœ¯è§£å†³æ–¹æ¡ˆæ供商之间的桥æ¢ï¼Œé€šè¿‡æ供独家研究和专业性指导，推动æˆåŠŸçš„技术实施和æä¾›ç»è¯æ˜Žå¯å¸å¼•å’Œç•™ä½å®¢æˆ·çš„战略，无ç¼è¿žæŽ¥è¿™ä¸¤å¤§ä¸»ä½“。

For more information about ABI Research's services, contact us at +1.516.624.2500 in the Americas, +44.203.326.0140 in Europe, +65.6592.0290 in Asia-Pacific, or visit www.abiresearch.com.

Contact Info: 

Global                                                             
Deborah Petrara                                                           
Tel: +1.516.624.2558                                                   
pr@abiresearch.com       

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Tech Trends That WON'T Happen in 2025: AI-RAN, Consumer Smart Glasses, Humanoids, and Semiconductor Onshoring - To Name a Few

SEONGNAM, South Korea, Dec. 12, 2024 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced today that it has received approval from the Human Research Ethics Committee (HREC) in Australia for the clinical trial protocols of a Phase 1/2 trials for its mRNA-based Japanese encephalitis vaccine candidate, GBP560.

SK bioscience is establishing its mRNA vaccine platform through the development of vaccines against Japanese encephalitis virus as well as Lassa fever virus.

The Japanese Encephalitis Virus (viral family: Flaviviruses) and Lassa fever vaccines (viral family: Arenaviruses) will serve as prototype vaccines that could potentially be adapted in a matter of weeks for use against a future Disease X that might emerge from those same viral families. This approach is key to the 100 Days Mission, a global goal to accelerate the development of vaccines against pandemic threats to just over three months.

This joint project is based on an agreement with the Coalition for Epidemic Preparedness Innovations (CEPI), which committed up to USD 40 million initial funding (approximately KRW 57.4 billion) in funding in 2022 to support preclinical and early clinical trials. A further USD 100 million in funding could be made available at a later date to support late-stage trials/licensure to further validate the mRNA platform and have it ready for use in outbreak situations.

The partnership builds upon SK bioscience's expertise in cutting-edge vaccine platforms such as cell culture, bacterial culture, and recombinant technology. By expanding the company's capabilities to include the mRNA platform, the collaboration aims to be ready to rapidly respond to Disease X and contribute to equitable access to vaccines, including through a contractual commitment to, if successful, prioritize supply for low-and middle-income countries, produce vaccine volumes required to meet public health needs, and ensure affordable pricing.

The mRNA vaccine platform technology, which was first commercialized in the COVID-19 vaccines during the pandemic, is available for rapid mass production compared to traditional platforms by utilizing genetic sequences. This capability makes mRNA technology well-suited for pandemic response. Furthermore, the mRNA vaccine platform shows significant potential to be applied to the development of therapeutic drugs, signaling rapid market expansion.

According to global market research firm 'Nova One Advisor', the global mRNA therapeutics market is projected to surpass around USD 58.90 billion (approximately KRW 84.5 trillion) by 2033, registering a CAGR of 17.06% by 2033.

The company will evaluate the immunogenicity and safety of GBP560 in 402 healthy adult participants in Australia. In stage 1, the participants will receive two shots of low, medium, high-dose vaccine, or a control vaccine administered 28 days apart. Based on the stage 1 results, the optimal dosage and regimen will be determined for further assessment of the immunogenicity and safety compared to the control group in stage 2.

During the Phase 1/2 trials, SK bioscience plans to confirm neutralizing antibody titers and immune responses, along with collecting data on major adverse events, safety indicators, and the rate of adverse reactions. The company aims to secure interim results by 2026.

Previously, the company conducted preclinical studies beginning in December 2023, where the vaccine candidate demonstrated superior safety and immunogenicity through repeated-dose toxicity studies, safety pharmacology tests, animal efficacy trials, and protective immunity tests.

Dr. Kent Kester, Executive Director of Vaccine Research and Development at CEPI said, "mRNA technology is at the heart of CEPI's work to build a library of vaccine candidates that could be swiftly adapted next time Disease X emerges. Our work with SK bioscience aims to validate the rapid response mRNA platform against viruses from two of the viral families with the potential to spawn future epidemics and pandemics, contributing to the 100 Days Mission and to building a safer world for all."

Jaeyong Ahn, CEO of SK bioscience, said, "The mRNA vaccine platform, with its rapid development cycle, is a critical tool for pandemic preparedness. By leveraging our strong network of various partners, including international organizations, global companies, and the Korean government, SK bioscience is committed to successfully establishing the mRNA technology platform and contributing to global health, equitable access to vaccines and vaccine sovereignty."

CEPI also supported the development of SK bioscience's COVID-19 vaccine and is funding an ongoing project to support a broadly protective coronavirus vaccine.

About SK bioscience

SK bioscience is an innovative vaccine and biotech company, committed to vaccine development and manufacturing to enable more equitable access to vaccines around the world. Leveraging strengths on cutting-edge technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe. With the cooperation of domestic and international governments, regulatory agencies, healthcare providers, doctors, and medical experts, all of the SK colleagues are passionately committed to providing high-quality vaccines to those who need them and better public healthcare solutions.

- SK bioscience Website

- SK bioscience Linkedin

Contact

Communications Team

Changhyun Jin (jin99@sk.com), Jeannie S. Pak (j.pak@sk.com)

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate